A new preclinical study, led by scientists at Wake Forest University School of Medicine (Winston-Salem, USA), shows that a new technology called mitochondrial transplantation holds promise as a potential therapy that could change the kidney transplant landscape. The study findings are published in the Annals of Surgery.
Mitochondrial transplantation is a regenerative medicine technology where healthy mitochondria are taken from cultured cells or tissue from organ donors and then injected into a diseased or damaged tissue or organ, a press release details. Mitochondria produce the energy needed for a cell to function.
“Our study shows that this technology could transform renal transplant medicine,” says Giuseppe Orlando (Atrium Health Wake Forest Baptist, Winston-Salem, USA), principal investigator of the study. “Here, we provide evidence that mitochondrial transfer lessens the damage that renal cells or the kidneys may suffer from disease or injury.”
For the study, the research team collaborated with the University of Turin (Turin, Italy), where scientists conducted preliminary tests in cultures of human proximal tubular cells, which are found in the kidneys and play an important in removing toxins. When the damaged cells were exposed to healthy mitochondria, cellular energy increased, and toxicity decreased.
“Essentially, the mitochondrial transplant was successful in reducing stress in the damaged kidney cells,” explains Orlando, who is also a researcher at Wake Forest Institute for Regenerative Medicine.
Additional research by the Wake Forest team found that kidneys injected with healthy mitochondria showed signs of recovery. Orlando adds that these results are significant because, in the USA, 20% of the kidneys procured for transplantation are eventually discarded because they are too damaged, and this potential new treatment may help.
“Based on these preliminary findings, I’m optimistic that mitochondrial transplantation could one day increase the number of transplantable organs,” Orlando states. This is especially true, he details, in a new type of organ donation called ‘uncontrolled donation after cardiac death,’ an area of active research.
In this setting, the kidneys do not receive adequate blood supply, and mitochondria and the kidneys are damaged. Orlando says that mitochondrial transplantation could enable surgeons to repair and eventually transplant these organs, potentially saving thousands of lives. It has been estimated, the press release suggests, that this type of donation may make 20,000 new kidneys suitable for transplants each year in the USA. It adds that “the next step is to validate these findings in a small pilot study”.
